Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy for HCV chronic hepatitis

Carlo Carella, Giovanni Amato, Bernadette Biondi, Mario Rotondi, Filomena Morisco, Concetta Tuccillo, Nicola Chiuchiolo, Giuseppe Signoriello, Nicola Caporaso, Gaetano Lombardi

Research output: Contribution to journalArticlepeer-review

Abstract

Seventy-five patients (50 M, 25 F), affected by chronic hepatitis caused by hepatitis C virus (HCV), without clinically overt thyroid disease, underwent r-interferon (IFN)-α-2a treatment (3–6 MU, 3 times/week) for 12 months. They were tested for thyroid function and for thyroid autoantibodies before (A), 6 (B) and 12 (C) months after the beginning of treatment and after 6 (D) months off therapy. Antithyroglobulin antibodies (Tg-Ab) and TSH were measured by IRMA, antiperoxidase antibodies (TPO-Ab), free T3 (FT3) and free T4 (FT4) by RIA, thyrotropin receptor antibodies (TR-Ab) by RRA. None of the patients showed TR-Ab positivity throughout the study. The number of the patients with one or both antithyroid antibodies progressively increased during treatment (A 10.7%; B 26.7%; C 45.3%) and decreased when off therapy (D 22.7%) with none of them positive for Tg-Ab alone (TPO-Ab 6.7%; Tg-Ab + TPO-Ab 16%). Tg-Ab increased during rIFN (median: A 29.0; B 35.0; C 73.0 U/ml) but decreased when off therapy (D 29.0 U/ml). Instead, TPO-Ab significantly increased throughout the study (A 1.0; B 3.0; C 6.0; D 7.0 U/ml). However, some patients showed for the first time an appearance of antibodies when off therapy. Five patients showed both antibodies and thyroid dysfunction: 2 at B, 2 at C, and 1 at D. Only 1 developed mild transient hyperthyroidism while the other 4 developed hypothyroidism, persistent however only in 1 case. Our study confirms that rIFN-α-2a frequently induces thyroid autoimmunity. TPO-Ab seems more useful than Tg-Ab in monitoring the immunological response. Thyroid dysfunction (especially hypothyroidism and in females), always accompanied with the appearance of thyroid autoantibodies, is often transitory in spite of not discontinued treatment. The pretreatment positivity for Tg-Ab was not associated with the subsequent development of thyroid dysfunction, therefore it cannot be considered a risk factor in IFN-α therapy. Finally, the appearance in some cases of TPO-Ab after stopping treatment suggests that the thyroid surveillance in these patients should be prolonged.

Original languageEnglish
Pages (from-to)110-114
Number of pages5
JournalHormone Research in Paediatrics
Volume44
Issue number3
DOIs
Publication statusPublished - 1995

Keywords

  • Autoimmunity
  • Hepatitis
  • Interferon
  • Thyroid

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy for HCV chronic hepatitis'. Together they form a unique fingerprint.

Cite this